SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
The ninth acquisition since 2018
Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
Investment in response to increased demand for North American-based chemistry services
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
WuXi STA opens a new large scale continuous manufacturing plant
Manish led SeQuent since 2014 and played a major role in transforming the company
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Subscribe To Our Newsletter & Stay Updated
